ERCC2 validated as chemotherapy response biomarker in bladder cancer

By Shreeya Nanda

Somatic mutations in the helicase-encoding ERCC2 gene are associated with response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive urothelial bladder carcinoma.

Among 48 patients who received three cycles of chemotherapy in two clinical trials of neoadjuvant cisplatin-based treatment, 10 had tumours with nonsynonymous mutations in ERCC2.

ERCC2 mutations were significantly associated with response, such that 40% of 20 responders harboured a mutation compared with only 7% of 28 nonresponders, a significant difference. Moreover, overall survival was significantly longer for participants with versus without an ERCC2 alteration.

These findings replicate those of a discovery cohort that showed an association between ERCC2 mutations and pathological response, say Jonathan Rosenberg (Memorial Sloan Kettering Cancer Center, New York, USA) and co-authors in JAMA Oncology.

But they add that as a biomarker ERCC2 has limitations - it is not 100% specific and mutations are found in less than half of responders, suggesting that other factors are involved.

The team concludes: "Further characterization of specific ERCC2 mutations to improve specificity and development of a more sensitive integrated panel of DNA repair biomarkers may inform clinical decision-making."

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Immunotherapies effective against lung cancer, melanoma may also work against rare skin tumor